---
title: Is tumour sequencing effective for the identification of germline <em>BRCA1/2</em>
  pathogenic variant carriers?
date: '2024-09-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39311051/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240923200302&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In our tumour-to-germline testing approach, we observed
  the BRCA1/2 pathogenic variant frequency reported in other large unselected ovarian
  cancer cohorts, thus confirming its effectiveness in identifying putative germline
  carriers irrespective of eligibility for germline testing. As the range of tumours
  subjected to genetic testing broadens, this approach is expected to also be effective
  in other tumour settings for enhancing the identification of carriers, reducing
  the burden ...'
disable_comments: true
---
CONCLUSIONS: In our tumour-to-germline testing approach, we observed the BRCA1/2 pathogenic variant frequency reported in other large unselected ovarian cancer cohorts, thus confirming its effectiveness in identifying putative germline carriers irrespective of eligibility for germline testing. As the range of tumours subjected to genetic testing broadens, this approach is expected to also be effective in other tumour settings for enhancing the identification of carriers, reducing the burden ...